Maintaining low HIV seroprevalence in populations of injecting drug users

JAMA

Volumn 274, Issue 15, 1995, Pages 1226-1231

  Des Jarlais, Don C ^a,b   Hagan, Holly ^c,j   Friedman, Samuel R ^b   Friedmann, Patricia ^a   Goldberg, David ^e   Frischer, Martin ^e   Green, Steven ^e   Tunving, Kerstin ^f   Ljungberg, Bengt ^f   Wodak, Alex ^g   Ross, Michael ^h,k   Purchase, David ^d   Millson, Margaret E ⁱ   Myers, Ted ⁱ  

^a BETH ISRAEL MEDICAL CENTER   (United States)

^b NATIONAL DEVELOPMENT AND RESEARCH INSTITUTES   (United States)

^c Tacoma Pierce County Health Department   (United States)

^d Point Defiance AIDS Projects   (United States)

^e RUCHILL HOSPITAL   (United Kingdom)

^f LUND UNIVERSITY   (Sweden)

^g ST VINCENT S HOSPITAL   (Australia)

^h UNIVERSITY OF NEW SOUTH WALES   (Australia)

ⁱ UNIVERSITY OF TORONTO   (Canada)

^j Public Health Seattle King County   (United States)

^k UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; HEALTH BEHAVIOR; HIGH RISK POPULATION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; INTRAVENOUS DRUG ABUSE; PREVALENCE; PRIORITY JOURNAL; RISK ASSESSMENT;

EID: 0028787806     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.274.15.1226     Document Type: Article

References (48)

1. Stimson GV. The health and social costs of drug injecting: the challenge to developing countries. Presented at the Sixth International Conference on the Reduction of Drug-Related Harm; March 26-30, 1995; Florence, Italy.
2. Des Jarlais DC, Friedman SR, Goldberg D, et al. Final Report of the World Health Organization Programme on Substance Abuse Multi-City Study of HIV Infection Among Injecting Drug Users. Geneva, Switzerland: World Health Organization; May 1994.
3. Des Jarlais DC, Friedman SR, Novick D, et al. HIV-1 infection among intravenous drug users in Manhattan. JAMA. 1989;261:1008-1012.
4. Robertson JR, Bucknall ABV, Welsby P, et al. Epidemic of AIDS-related virus (HTLV-III/LAV) infection among intravenous drug users. BMJ. 1986; 292:527-529.
5. Vanichseni S, Sakuntanaga P. Results of three seroprevalence surveys for HIV in IVDU in Bangkok. In: Program and abstracts of the Sixth International Conference on AIDS; June 20-23, 1990; San Francisco, Calif. Abstract FC 105.
6. Naik TN, Sarkar S, Singh HL, et al. Intravenous drug users: a new high-risk group for HIV infection in India. AIDS. 1991;5:117-118.
7. Friedman SR, Des Jarlais DC. HIV among drug injectors: the epidemic and the response. AIDS Care. 1991;3:239-250.
8. Lamothe F, Bruneau J, Soto J. Progression of prevalence of HIV-1 infection among injection drug users in Montreal, Quebec. Can Commun Dis Rep. 1992;18:98-101.
9. Lampinen TM, Joo E, Seweryn S, Hershow RC, Weibel W. HIV seropositivity in community-recruited and drug treatment samples of injecting drug users. AIDS. 1992;6:123-126.
10. Lurie P, Reingold AL, Bowser B, et al. The Public Health Impact of Needle-Exchange Programs in the United States and Abroad, Volume 1. Atlanta, Ga: Centers for Disease Control and Prevention; September 1993.
11. Stimson GV. The prevention of HIV infection in injecting drug users: recent advances and remaining obstacles. In: Program and abstracts of the Sixth International Conference on AIDS; June 20-24, 1990; San Francisco, Calif.
12. Frischer M, Green S, Goldberg D, et al. Estimates of HIV infection among injecting drug users in Glasgow from 1985-1990. AIDS. 1992;6:1371-1375.
13. Frischer M, Floor M, Green S, et al. Reduction in needle sharing among community-wide samples of drug injectors. Int J STD AIDS. 1992;3:288-290.
14. Frischer M, Haw S, Bloor M, et al. Modelling the behaviour and attributes of injecting drug users: a new approach to identifying HIV risk practices. Int J Addict. 1993;28:129-152.
15. Hagan H, Hale CB. HIV-1 Seroprevalence Surveys in Pierce County, June 1988 to December 1992. Tacoma, Wash: Tacoma-Pierce County Health Department; 1993.
16. Millson P, Myers T, Rankin J, Major C, Fearon M, Rigby J. Trends in HIV seroprevalence and risk behaviour in IDUs in Toronto, Canada. In: Program and abstracts of the Ninth International Conference on AIDS; June 6-11, 1993; Berlin, Germany. Abstract PO-C15-2936.
17. Kaldor J, Elford J, Wodak A, Crofts JN, Kidd S. HIV prevalence among IDUs in Australia: a methodological review. Drug Alcohol Rev. 1993;12: 175-184.
18. Ljungberg B, Christensson B, Tunving K, et al. HIV prevention among injecting drug users: three years of experience from a syringe exchange program in Sweden. J AIDS. 1991;4:890-895.
19. Tunving K, Nyholm K, Andersson B. Two successful syringe- and needle-exchange programs in Lund/Malmö, Sweden: their effects on the help-seeking drug-using communities and the surrounding drug treatment facilities. In: Program and abstracts of the Eighth International Conference on AIDS; July 19-24, 1992; Amsterdam, the Netherlands. Abstract PuC 8231.
20. Papaevangelou G, Ancelle-Park R, Seyrer Y. HIV prevalence and risk factors for infection among intravenous drug users in the European Community. In: Program and abstracts of the Seventh International Conference on AIDS; June 16-21, 1991: Florence, Italy. Abstract MD 4074.
21. Hagan H, Des Jarlais DC, Purchase D, et al. An interview study of participants in the Tacoma, Washington syringe exchange. Addiction. 1993;88:1691-1697.
22. Ross MW, Wodak A, Gold J, Miller ME. Differences across sexual orientation on HIV risk behaviours in injecting drug users. AIDS Care. 1992; 4:139-148.
23. Ross MW, Stowe A, Wodak A, Miller ME, Gold J. Predictors of HIV status among injecting drug users, and health promotion. J R Soc Health. In press.
24. Millson P, Myers T, Rankin J, et al. Descriptive epidemiology of injection drug users in Toronto. Presented at the Second Annual Canadian National Conference on HIV/AIDS; May 28-29, 1992; Vancouver, British Columbia.
25. Hagan H, Des Jarlais DC, Purchase D, Reid T, Friedman SR. The Tacoma syringe exchange. J Addict Dis. 1991;10:81-88.
26. Frischer M, Elliot L. Discriminating needle-exchange attenders from non-attenders. Br J Addict. 1993;88:681-687.
27. Friedman SR, de Jong W, Wodak A. Community development as a response to HIV among drug injectors. AIDS. 1993;7(suppl 1):S263-S269.
28. Des Jarlais DC, Friedman SR. AIDS prevention programs for injecting drug users. In: Wormser GP, ed. AIDS and Other Manifestations of HIV Infection. 2nd ed. New York, NY: Raven Press Ltd; 1992: 645-658.
29. Millson P, Coates R, Rankin J, et al. Evaluation of a Programme to Prevent Human Immunodeficiency Virus Transmission in Injection Drug Users in Toronto: Final Report to the National Health Research and Development Programme, Health and Welfare Canada. Ottawa, Ontario: National Health Research and Develoment Programme; December 1991. NHRDP grant 6606-4333-AIDS.
30. Taylor A, Frischer M, McKeganey N, Platt S, Goldberg D, Green S. HIV risk behaviours among female prostitute drug injectors in Glasgow. Addiction. In press.
31. Carr S, Green S, Goldberg D, et al. HIV prevalence among female street prostitutes attending a health care drop-in centre in Glasgow. AIDS. 1992; 6:1553-1554.
32. Christensson B, Ljungberg B. Syringe exchange for prevention of HIV infection in Sweden: practical experiences and community reactions. Int J Addict. 1991;26:1293-1302.
33. Neaigus A, Friedman SR, Curtis R, et al. The relevance of drug injectors' social networks and risk networks for understanding and preventing HIV infection. Soc Sci Med. 1994;38:67-78.
34. Stall R, Ekstrand ML, Pollack L, McKusick L, Coates TJ. Relapse from safer sex: the next challenge for AIDS prevention efforts. J Acquir Immune Defic Syndr. 1990;3:1181-1187.
35. Ekstrand ML, Coates TJ. Maintenance of safer sexual behaviors and predictors of risky sex: the San Francisco Men's Health Study. Am J Public Health. 1990;80:973-977.
36. Osmond DH, Page K, Wiley J, et al. Human immunodeficiency virus infection in homosexual/ bisexual men, ages 18-29: the San Francisco Young Men's Health Study. In: Program and abstracts of the Ninth International Conference on AIDS; June 6-11, 1993; Berlin, Germany. Abstract WS-C07-3.
37. Office of National Drug Control Policy (ONDCP). Needle Exchange Programs: Are They Effective? Washington, DC: Executive Office of the President, Office of National Drug Control Policy; July 1992. ONDCP Bulletin No. 7.
38. Stimson GV. AIDS and injecting drug use in the United Kingdom, 1988 to 1993: the policy response and the prevention of the epidemic. Soc Sci Med. In press.
39. Dolan KA, Stimson GV, Donoghoe MC. Reductions in HIV risk behaviour and stable HIV prevalence in syringe-exchange clients and other injectors in England. Drag Alcohol Rev. 1993;12:133-142.
40. Baker M, Tobias M, Brady H. Detection of HIV antibodies in used syringes in New Zealand. In: Program and abstracts of the Seventh International Conference on AIDS; July 16-21, 1991; Florence, Italy. Abstract WC 3364.
41. Brown BS, Beschner GM, eds. Handbook on Risk of AIDS. Westport, Conn: Greenwood Press; 1993.
42. DiClemente R, Peterson J, eds. Preventing AIDS: Theories and Methods of Behavioral Interventions. New York, NY: Plenum Press; 1994.
43. Anderson RM, May RM, Boily MC, Garnett GP, Rowley JT. The spread of HIV-1 in Africa: sexual contact and the predicted demographic impact of AIDS. Nature. 1991;352:581-589.
44. Cordray DS. Quasi-experimental analysis: a mixture of methods and judgment. New Dir Prog Eual. 1986;31:9-28.
45. Des Jarlais DC, Choopanya K, Vanichseni S, et al. AIDS risk reduction and reduced HIV seroconversion among injecting drug users in Bangkok. Am J Public Health. 1994;84:452-455.
46. Chitwood DD. HIV risk and injection drug users: evidence for behavioral change. Am J Public Health. 1994;84:350.
47. Des Jarlais DC, Hagan H, Friedman SR, et al. Biological validation of self-reported behavior change among IDUs. In: Program and abstracts of the 10th International Conference on AIDS; August 7-12, 1994; Yokohama, Japan. Abstract PD0495.
48. Des Jarlais DC, Friedman SR, Choopanya K, et al. International epidemiology of HIV and AIDS among injecting drug users. AIDS. 1992;6:1053-1068.